Business
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCR REDWOOD CITY,
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCR\nREDWOOD CITY, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today presented new positive clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Willi syndrome (PWS) at ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA. An oral presentation titled, “Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome,” presented by Dr. Eric Felner, Emory University School of Medicine, summarized data demonstrating positive hormonal, cardiometabolic and body composition changes in PWS patients following one year of treatment with DCCR. The patients were treated in C601, a Phase 3 randomized, double-blind, placebo-controlled study and C602, its ongoing open-label extension. Patients (n=82) experienced improvements in body composition, as evidenced by statistically significant changes in lean body mass (p","length":1573,"tagName":"div"}]